COLL Q3 2023 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$137M+7.6% YoY

Gross Profit

$80M58.7% margin

Operating Income

$45M32.9% margin

Net Income

$21M15.1% margin

EPS (Diluted)

$0.53

QoQ Revenue Growth

+0.9%

Cash Flow

Operating Cash Flow

$74M

Free Cash Flow

$74M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$999M

Stockholders' Equity

$179M

Cash & Equivalents

$259M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$137M	$127M	+7.6%
Gross Profit	$80M	$59M	+36.5%
Operating Income	$45M	$20M	+119.9%
Net Income	$21M	$457,000	+4415.1%

Revenue Segments

Belbuca

$45M33%

Xtampza ER

$40M29%

Nucynta IR

$25M18%

Nucynta ER

$23M17%

Symproic

$4M3%